Welcome to our dedicated page for Advanced Biomed news (Ticker: ADVB), a resource for investors and traders seeking the latest updates and insights on Advanced Biomed stock.
Advanced Biomed Inc. (NASDAQ: ADVB) is a biotechnology company in the healthcare diagnostics and research space, with a focus on cancer-related precision medicine and advanced diagnostics. The ADVB news page on Stock Titan aggregates company-specific announcements, regulatory disclosures, and market-relevant updates drawn from press releases and SEC filings.
Investors and researchers following Advanced Biomed can use this news feed to track developments in its microfluidic biochip technologies, circulating tumor cell detection platforms, and related assay products and services. The company has highlighted devices such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, as well as biochips and immunostaining kits that support early screening and detection, diagnosis and staging, and treatment of cancer.
Recent news items have included the closing and pricing of the company’s initial public offering on the Nasdaq Capital Market under the symbol ADVB, the launch of the A+PerfusC integrated perfusion 3D cell culture platform for precision medicine and drug discovery, and corporate actions involving its Hong Kong and Shanghai subsidiaries. Regulatory and listing-related updates, such as notices from Nasdaq regarding minimum bid price requirements, are also disclosed through company press releases and Form 8-K filings.
On this page, readers can expect coverage of product launches, platform enhancements, capital markets transactions, subsidiary-level changes, and other material events that Advanced Biomed chooses to announce publicly. Regularly reviewing ADVB news can help users understand how the company is progressing with its cancer diagnostics technologies, 3D cell culture systems, and geographic realignment of clinical and operational activities.
Advanced Biomed (Nasdaq: ADVB) will effect a 1-for-20 reverse stock split at the open of Nasdaq on February 20, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).
The board approved the split on January 30, 2026 after shareholder written consent on January 12, 2026. Post-split shares outstanding will change from 27,290,710 to approximately 1,364,536, and the security will trade under the same symbol ADVB with a new CUSIP 00752P203.
Advanced Biomed (Nasdaq: ADVB) launched a 120-case, IRB-approved feasibility study with Chi‑Mei Medical Center to evaluate the A+PerfusC perfusion 3D cell culture platform using circulating tumor cells from liquid biopsy. Case collection began February 2026; interim comparative data are expected May–June 2026 and full completion is targeted by year-end 2026. The study compares ex-vivo drug sensitivity results to actual patient outcomes and follows the platform’s September 2025 commercial launch. Under the collaboration, both parties will share project-related intellectual property and research outcomes.
Advanced Biomed (Nasdaq: ADVB) announced on Dec 30, 2025 that it sold 100% of Advanced Biomed (HK) Limited to buyer Wei Ha Hui with closing on Dec 23, 2025.
The aggregate purchase price was US$23,000 based on a company-commissioned valuation report. All intellectual property held by the Hong Kong subsidiary, including IP owned by Shanghai Sglcell Biotech Co., Ltd., transferred to the buyer at closing. Management said the divestiture responds to evolving China clinical-data regulations and that all clinical trials will be centralized and conducted through the Taiwan subsidiary as part of a strategic realignment.
Advanced Biomed (Nasdaq: ADVB) has launched A+PerfusC™, an integrated perfusion 3D cell culture platform designed for precision medicine and drug discovery applications. The system features a compact, all-in-one design that supports up to 12 days of continuous, hands-free culture with capacity for 4,800 tumor spheroids per plate.
Key features include 8 independent channels per plate, compatibility with 96/384 well plates for high-throughput screening, and microscope mounting capability. The platform has completed internal testing and validation, with mass production development currently underway.
The launch targets the growing global 3D cell culture market, valued at $2.32 billion in 2025 and projected to reach $4.71 billion by 2030, with a CAGR of 15.6%.
Advanced Biomed Inc. (NASDAQ: ADVB) has successfully completed its Initial Public Offering (IPO), raising $6.56 million in gross proceeds through the sale of 1,640,000 common stock shares at $4.00 per share. Trading began on the Nasdaq Capital Market on March 6, 2025, under ticker 'ADVB'.
The company has granted the underwriter a 45-day option to purchase up to 246,000 additional shares. The IPO proceeds will fund:
- IVD clinical research, chip design and development, facility upgrades, and market expansion
- Marketing and sales initiatives
- General working capital
Advanced Biomed, established in 2014, specializes in microfluidic technology for cancer detection and treatment, offering innovative devices including A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding biochips and immunostaining kits.
Advanced Biomed has announced the pricing of its Initial Public Offering (IPO) of 1,640,000 common stock shares at $4.00 per share, expecting to raise gross proceeds of $6.56 million. The shares will trade on the Nasdaq Capital Market under ticker symbol ADVB starting March 6, 2025.
The biotechnology company, focused on cancer screening, detection, diagnosis, and treatment, has granted underwriters a 45-day option to purchase up to additional 246,000 shares. The offering is expected to close around March 7, 2025.
Proceeds will fund:
- IVD clinical research, chip design and development
- Facility upgrades and market expansion
- Marketing and sales initiatives
- General working capital